Senior Medical Device Sales and Marketing Executive Joins Lombard Medical
London, UK, 29 April 2010 – Lombard Medical Technologies PLC (AIM: LMT), announced today that Simon Hubbert has accepted the position of Vice President Sales and Marketing, International and will join the Company full time on June 1st, 2010. In this role, he will lead Lombard Medical’s sales and marketing activities outside of North America.
Mr. Hubbert brings a wealth of experience to the Lombard Medical team, having held various sales and marketing roles for Johnson & Johnson and Medtronic, including the role of European Business and Marketing Manager for Medtronic. Most recently, Mr. Hubbert held the position of Vice President of Sales and Marketing International for LMA, a publicly traded company focused on innovative medical devices for the anaesthesia markets. In his role with LMA, Mr. Hubbert was responsible for growing revenue through a hybrid distribution model which included a direct sales organization in several major markets, and support of third party distribution partners in other markets. Mr. Hubbert started his career in patient care, working in an operating theatre at a renowned neurosurgical unit in the UK.
John Rush, Chief Executive Officer of Lombard Medical commented:
“Simon’s experience is exactly what we are looking for at Lombard Medical. He has an excellent track record of growing revenues for well known, high quality organizations including J&J and Medtronic. He has successfully managed a distribution model similar to one we are planning to build, and he has worked in highly technical and clinical environments. This experience will provide an additional level of depth to our senior team as we accelerate the launch and roll out of Aorfix™ in Europe.”
- Ends -
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1 billion dollar abdominal aortic aneurysm (AAA) repair market. AAA’s are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAA’s in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA
.
Further background on the Company can be found at www.lombardmedical.com.
Forfurther information:
Lombard Medical Technologies PLC
John Rush, Chief Executive Officer
Tim Hall, Finance Director
Tel: 01235 750 800
Evolution Securities Limited
Barry Saint
Tel : 020 7071 4300
Financial Dynamics
Jonathan Birt /Susan Quigley
Tel : 020 7831 3113